|
1
|
Tsimberidou AM, Fountzilas E, Nikanjam M
and Kurzrock R: Review of precision cancer medicine: Evolution of
the treatment paradigm. Cancer Treat Rev. 86:1020192020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu
X, Huang M, Meng L, He X, Zhu H, et al: Multiple Signaling Roles of
CD3ε and Its Application in CAR-T Cell Therapy. Cell. 182:855–871.
e232020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parker KR, Migliorini D, Perkey E, Yost
KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, et
al: Single-Cell analyses identify brain mural cells expressing CD19
as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell.
183:126–142. e172020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sterner RC and Sterner RM: CAR-T cell
therapy: Current limitations and potential strategies. Blood Cancer
J. 11:692021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan
CX and Zhu Z: CAR race to cancer immunotherapy: From CAR T, CAR NK
to CAR macrophage therapy. J Exp Clin Cancer Res. 41:1192022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahmad A: CAR-T Cell Therapy. Int J Mol
Sci. 21:43032020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feins S, Kong W, Williams EF, Milone MC
and Fraietta JA: An introduction to chimeric antigen receptor (CAR)
T-cell immunotherapy for human cancer. Am J Hematol. 94((S1)):
S3–S9. 2019.PubMed/NCBI
|
|
8
|
Majzner RG and Mackall CL: Tumor antigen
escape from CAR T-cell therapy. Cancer Discov. 8:1219–1226. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abreu TR, Fonseca NA, Gonçalves N and
Moreira JN: Current challenges and emerging opportunities of CAR-T
cell therapies. J Control Release. 319:246–261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Labanieh L, Majzner RG, Klysz D, Sotillo
E, Fisher CJ, Vilches-Moure JG, Pacheco KZB, Malipatlolla M, Xu P,
Hui JH, et al: Enhanced safety and efficacy of protease-regulated
CAR-T cell receptors. Cell. 185:1745–1763. e222022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Flugel CL, Majzner RG, Krenciute G, Dotti
G, Riddell SR, Wagner DL and Abou-El-Enein M: Overcoming on-target,
off-tumour toxicity of CAR T cell therapy for solid tumours. Nat
Rev Clin Oncol. 20:49–62. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chohan KL, Siegler EL and Kenderian SS:
CAR-T Cell Therapy: The efficacy and toxicity balance. Curr Hematol
Malig Rep. 18:9–18. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen YJ, Abila B and Mostafa Kamel Y:
CAR-T: What Is Next? Cancers (Basel). 15:6632023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schubert ML, Schmitt M, Wang L, Ramos CA,
Jordan K, Müller-Tidow C and Dreger P: Side-effect management of
chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol.
32:34–48. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bao C, Gao Q, Li LL, Han L, Zhang B, Ding
Y, Song Z, Zhang R, Zhang J and Wu XH: The application of nanobody
in CAR-T therapy. Biomolecules. 11:2382021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Majzner RG, Rietberg SP, Sotillo E, Dong
R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber
EW, Tousley AM, et al: Tuning the antigen density requirement for
CAR T-cell Activity. Cancer Discov. 10:702–723. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Depil S, Duchateau P, Grupp SA, Mufti G
and Poirot L: ‘Off-the-shelf’ allogeneic CAR T cells: development
and challenges. Nat Rev Drug Discov. 19:185–199. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benmebarek MR, Karches CH, Cadilha BL,
Lesch S, Endres S and Kobold S: Killing mechanisms of chimeric
antigen receptor (CAR) T Cells. Int J Mol Sci. 20:12832019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rafiq S, Yeku OO, Jackson HJ, Purdon TJ,
van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al:
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances
anti-tumor efficacy in vivo. Nat Biotechnol. 36:847–856. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van de Donk NWCJ, Usmani SZ and Yong K:
CAR T-cell therapy for multiple myeloma: State of the art and
prospects. Lancet Haematol. 8:e446–e461. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Srivastava S and Riddell SR: Engineering
CAR-T cells: Design concepts. Trends Immunol. 36:494–502. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Duan Y, Chen R, Huang Y, Meng X, Chen J,
Liao C, Tang Y, Zhou C, Gao X and Sun J: Tuning the ignition of
CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell
Mol Life Sci. 79:142021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weber EW, Parker KR, Sotillo E, Lynn RC,
Anbunathan H, Lattin J, Good Z, Belk JA, Daniel B, Klysz D, et al:
Transient rest restores functionality in exhausted CAR-T cells
through epigenetic remodeling. Science. 372:eaba17862021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tousley AM, Rotiroti MC, Labanieh L,
Rysavy LW, Kim WJ, Lareau C, Sotillo E, Weber EW, Rietberg SP,
Dalton GN, et al: Co-opting signalling molecules enables
logic-gated control of CAR T cells. Nature. 615:507–516. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Honikel MM and Olejniczak SH:
Co-Stimulatory receptor signaling in CAR-T Cells. Biomolecules.
12:13032022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang R, Li X, He Y, Zhu W, Gao L, Liu Y,
Gao L, Wen Q, Zhong JF, Zhang C and Zhang X: Recent advances in
CAR-T cell engineering. J Hematol Oncol. 13:862020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Singh N, Frey NV, Engels B, Barrett DM,
Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I,
et al: Antigen-independent activation enhances the efficacy of
4-1BB-costimulated CD22 CAR T cells. Nat Med. 27:842–850. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smole A, Benton A, Poussin MA, Eiva MA,
Mezzanotte C, Camisa B, Greco B, Sharma P, Minutolo NG, Gray F, et
al: Expression of inducible factors reprograms CAR-T cells for
enhanced function and safety. Cancer Cell. 40:1470–1487. e772022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Drougkas K, Karampinos K, Karavolias I,
Koumprentziotis IA, Ploumaki I, Triantafyllou E, Trontzas I and
Kotteas E: Comprehensive clinical evaluation of CAR-T cell
immunotherapy for solid tumors: A path moving forward or a dead
end? J Cancer Res Clin Oncol. 149:2709–2734. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Westin J and Sehn LH: CAR T cells as a
second-line therapy for large B-cell lymphoma: A paradigm shift?
Blood. 139:2737–2746. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roselli E, Boucher JC, Li G, Kotani H,
Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, et al:
4-1BB and optimized CD28 co-stimulation enhances function of human
mono-specific and bi-specific third-generation CAR T cells. J
Immunother Cancer. 9:e0033542021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Martinez M and Moon EK: CAR T cells for
solid tumors: New strategies for finding, infiltrating, and
surviving in the tumor microenvironment. Front Immunol. 10:1282019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barros LRC, Couto SCF, da Silva Santurio
D, Paixão EA, Cardoso F, da Silva VJ, Klinger P, Ribeiro PDAC, Rós
FA, Oliveira TGM, et al: Systematic review of available CAR-T Cell
Trials around the World. Cancers (Basel). 14:26672022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Agliardi G, Liuzzi AR, Hotblack A, De Feo
D, Núñez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L,
Roberts TA, et al: Intratumoral IL-12 delivery empowers CAR-T cell
immunotherapy in a pre-clinical model of glioblastoma. Nat Commun.
12:4442021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Glienke W, Dragon AC, Zimmermann K,
Martyniszyn-Eiben A, Mertens M, Abken H, Rossig C, Altvater B,
Aleksandrova K, Arseniev L, et al: GMP-Compliant Manufacturing of
TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18.
Front Immunol. 13:8397832022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Etxeberria I, Glez-Vaz J, Teijeira Á and
Melero I: New emerging targets in cancer immunotherapy: CD137/4-1BB
costimulatory axis. ESMO Open. 4 (Suppl 3):e0007332020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sanchez-Paulete AR, Labiano S,
Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V,
Rodriguez M, Aznar MA, Jure-Kunkel M and Melero I: Deciphering
CD137 (4-1BB) signaling in T-cell costimulation for translation
into successful cancer immunotherapy. Eur J Immunol. 46:513–522.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu Y, An L, Huang R, Xiong J, Yang H,
Wang X and Zhang X: Strategies to enhance CAR-T persistence.
Biomark Res. 10:862022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS
and Su X: Size-dependent activation of CAR-T cells. Sci Immunol.
7:eabl39952022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou
M, Jin G, Rahman MM, McFadden G and Lu Y: Induction of tumor cell
autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome
primary and acquired resistance. Cancer Cell. 40:973–985. e72022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brudno JN and Kochenderfer JN: Recent
advances in CAR T-cell toxicity: Mechanisms, manifestations and
management. Blood Rev. 34:45–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Boyiadzis MM, Dhodapkar MV, Brentjens RJ,
Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp
SA, Mackall CL, et al: Chimeric antigen receptor (CAR) T therapies
for the treatment of hematologic malignancies: Clinical perspective
and significance. J Immunother Cancer. 6:1372018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Choi BD, Yu X, Castano AP, Bouffard AA,
Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick
MB, et al: CAR-T cells secreting BiTEs circumvent antigen escape
without detectable toxicity. Nat Biotechnol. 37:1049–1058. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Marei HE, Althani A, Afifi N, Hasan A,
Caceci T, Pozzoli G and Cenciarelli C: Current progress in chimeric
antigen receptor T cell therapy for glioblastoma multiforme. Cancer
Med. 10:5019–5030. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhu H, Fang X, Tuhin IJ, Tan J, Ye J, Jia
Y, Xu N, Kang L, Li M, Lou X, et al: CAR T cells equipped with a
fully human scFv targeting Trop2 can be used to treat pancreatic
cancer. J Cancer Res Clin Oncol. 148:2261–2274. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Feng Q, Sun B, Xue T, Li R, Lin C, Gao Y,
Sun L, Zhuo Y and Wang D: Advances in CAR T-cell therapy in bile
duct, pancreatic, and gastric cancers. Front Immunol.
13:10256082022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Entezam M, Sanaei MJ, Mirzaei Y, Mer AH,
Abdollahpour-Alitappeh M, Azadegan-Dehkordi F and Bagheri N:
Current progress and challenges of immunotherapy in gastric cancer:
A focus on CAR-T cells therapeutic approach. Life Sci.
318:1214592023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Davenport AJ, Jenkins MR, Cross RS, Yong
CS, Prince HM, Ritchie DS, Trapani JA, Kershaw MH, Darcy PK and
Neeson PJ: CAR-T cells inflict sequential killing of multiple tumor
target cells. Cancer Immunol Res. 3:483–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen C, Gu YM, Zhang F, Zhang ZC, Zhang
YT, He YD, Wang L, Zhou N, Tang FT, Liu HJ and Li YM: Construction
of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of
c-Met CAR-T in gastric cancer. Oncoimmunology. 10:19014342021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cohen AD, Garfall AL, Stadtmauer EA,
Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K,
Nelson A, et al: B cell maturation antigen-specific CAR T cells are
clinically active in multiple myeloma. J Clin Invest.
129:2210–2221. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pasqui DM, Latorraca CDOC, Pacheco RL and
Riera R: CAR-T cell therapy for patients with hematological
malignancies. A systematic review. Eur J Haematol. 109:601–618.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fabrizio VA, Boelens JJ, Mauguen A,
Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips
CL, Rossoff J, et al: Optimal fludarabine lymphodepletion is
associated with improved outcomes after CAR T-cell therapy. Blood
Adv. 6:1961–1968. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bupha-Intr O, Haeusler G, Chee L, Thursky
K, Slavin M and The B: CAR-T cell therapy and infection: a review.
Expert Rev Anti Infect Ther. 19:749–758. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Roddie C, Neill L, Osborne W, Iyengar S,
Tholouli E, Irvine D, Chaganti S, Besley C, Bloor A, Jones C, et
al: Effective bridging therapy can improve CD19 CAR-T outcomes
while maintaining safety in patients with large B-cell lymphoma.
Blood Adv. 7:2872–2883. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mangal JL, Handlos JL, Esrafili A, Inamdar
S, Mcmillian S, Wankhede M, Gottardi R and Acharya AP: Engineering
metabolism of chimeric antigen receptor (CAR) cells for developing
efficient immunotherapies. Cancers (Basel). 13:11232021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chow A, Perica K, Klebanoff CA and Wolchok
JD: Clinical implications of T cell exhaustion for cancer
immunotherapy. Nat Rev Clin Oncol. 19:775–790. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Martino M, Alati C, Canale FA, Musuraca G,
Martinelli G and Cerchione C: A review of clinical outcomes of CAR
T-Cell Therapies for B-Acute lymphoblastic leukemia. Int J Mol Sci.
22:21502021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Geldres C, Savoldo B and Dotti G: Chimeric
antigen receptor-redirected T cells return to the bench. Semin
Immunol. 28:3–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Neelapu SS, Tummala S, Kebriaei P, Wierda
W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et
al: Chimeric antigen receptor T-cell therapy-assessment and
management of toxicities. Nat Rev Clin Oncol. 15:47–62. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang X, Zhang H, Lan H, Wu J and Xiao Y:
CAR-T cell therapy in multiple myeloma: Current limitations and
potential strategies. Front Immunol. 14:11014952023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Haslauer T, Greil R, Zaborsky N and
Geisberger R: CAR T-Cell therapy in hematological malignancies. Int
J Mol Sci. 22:89962021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y,
Xiao L, Han Y and Lu L: Therapeutic efficacy of anti-CD19 CAR-T
cells in a mouse model of systemic lupus erythematosus. Cell Mol
Immunol. 18:1896–1903. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Denlinger N, Bond D and Jaglowski S: CAR
T-cell therapy for B-cell lymphoma. Curr Probl Cancer.
46:1008262022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Shalabi H, Qin H, Su A, Yates B, Wolters
PL, Steinberg SM, Ligon JA, Silbert S, DéDé K, Benzaoui M, et al:
CD19/22 CAR T cells in children and young adults with B-ALL: Phase
1 results and development of a novel bicistronic CAR. Blood.
140:451–463. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang
C, Ye Z and Qian Q: Current Progress in CAR-T cell therapy for
solid tumors. Int J Biol Sci. 15:2548–2560. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Majzner RG, Ramakrishna S, Yeom KW, Patel
S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V,
Mancusi R, et al: GD2-CAR T cell therapy for H3K27M-mutated diffuse
midline gliomas. Nature. 603:934–941. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zarrabi KK, Narayan V, Mille PJ, Zibelman
MR, Miron B, Bashir B and Kelly WK: Bispecific PSMA antibodies and
CAR-T in metastatic castration-resistant prostate cancer. Ther Adv
Urol. 15:175628722311822192023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Narayan V, Barber-Rotenberg JS, Jung IY,
Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude
SL, et al: PSMA-targeting TGFβ-insensitive armored CAR T cells in
metastatic castration-resistant prostate cancer: A phase 1 trial.
Nat Med. 28:724–734. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Miller IC, Zamat A, Sun LK, Phuengkham H,
Harris AM, Gamboa L, Yang J, Murad JP, Priceman SJ and Kwong GA:
Enhanced intratumoural activity of CAR T cells engineered to
produce immunomodulators under photothermal control. Nat Biomed
Eng. 5:1348–1359. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z,
Zhao H, Wei G, Wang Y, Zhang M, et al: CAR-T cell therapy-related
cytokine release syndrome and therapeutic response is modulated by
the gut microbiome in hematologic malignancies. Nat Commun.
13:53132022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Giavridis T, van der Stegen SJC, Eyquem J,
Hamieh M, Piersigilli A and Sadelain M: CAR T cell-induced cytokine
release syndrome is mediated by macrophages and abated by IL-1
blockade. Nat Med. 24:731–738. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu
X and Li Y: Mechanisms of cytokine release syndrome and
neurotoxicity of CAR T-cell therapy and associated prevention and
management strategies. J Exp Clin Cancer Res. 40:3672021.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu
YF, Xu J, Zhuang Y, Zhang W, Weng XQ, et al: Exploratory trial of a
biepitopic CAR T-targeting B cell maturation antigen in
relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA.
116:9543–9551. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin
D, Guo T, Kou H, Liu L, Tang L, et al: A bispecific CAR-T cell
therapy targeting BCMA and CD38 in relapsed or refractory multiple
myeloma. J Hematol Oncol. 14:1612021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jain T, Olson TS and Locke FL: How I treat
cytopenias after CAR T-cell therapy. Blood. 141:2460–2469.
2023.PubMed/NCBI
|
|
76
|
Gust J, Hay KA, Hanafi LA, Li D, Myerson
D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, et al:
Endothelial activation and blood-brain barrier disruption in
neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells.
Cancer Discov. 7:1404–1419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Corti C, Venetis K, Sajjadi E, Zattoni L,
Curigliano G and Fusco N: CAR-T cell therapy for triple-negative
breast cancer and other solid tumors: preclinical and clinical
progress. Expert Opin Investig Drugs. 31:593–605. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang
Q, Zhang L, Wei G, Tian Y, Zhao K, et al: Non-viral, specifically
targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Nature. 609:369–374. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Mensali N, Köksal H, Joaquina S, Wernhoff
P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L,
Juzeniene A, et al: ALPL-1 is a target for chimeric antigen
receptor therapy in osteosarcoma. Nat Commun. 14:33752023.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Cappell KM and Kochenderfer JN: Long-term
outcomes following CAR T cell therapy: What we know so far. Nat Rev
Clin Oncol. 20:359–371. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Shah NN and Fry TJ: Mechanisms of
resistance to CAR T cell therapy. Nat Rev Clin Oncol. 16:372–385.
2019.PubMed/NCBI
|
|
82
|
Jayaraman J, Mellody MP, Hou AJ, Desai RP,
Fung AW, Pham AHT, Chen YY and Zhao W: CAR-T design: Elements and
their synergistic function. EBioMedicine. 58:1029312020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang
H, Liu B, Li G, Li L, Chen M, et al: Tuning charge density of
chimeric antigen receptor optimizes tonic signaling and CAR-T cell
fitness. Cell Res. 33:341–354. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hamieh M, Dobrin A, Cabriolu A, van der
Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z,
Whitlock BM, Miele MM, et al: CAR T cell trogocytosis and
cooperative killing regulate tumour antigen escape. Nature.
568:112–116. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D,
Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S,
Pascual-Pasto G, et al: GPC2-CAR T cells tuned for low antigen
density mediate potent activity against neuroblastoma without
toxicity. Cancer Cell. 40:53–69.e9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ramos CA, Rouce R, Robertson CS, Reyna A,
Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, et al: In
Vivo Fate and Activity of Second-versus Third-Generation
CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol
Ther. 26:2727–2737. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Turtle CJ, Hanafi LA, Berger C, Gooley TA,
Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto
TM, et al: CD19 CAR-T cells of defined CD4+:CD8+ composition in
adult B cell ALL patients. J Clin Invest. 126:2123–2138. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Song DG, Ye Q, Poussin M, Harms GM, Figini
M and Powell DJ Jr: CD27 costimulation augments the survival and
antitumor activity of redirected human T cells in vivo. Blood.
119:696–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Bachy E, Le Gouill S, Di Blasi R, Sesques
P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, et
al: A real-world comparison of tisagenlecleucel and axicabtagene
ciloleucel CAR T cells in relapsed or refractory diffuse large B
cell lymphoma. Nat Med. 28:2145–2154. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Han D, Xu Z, Zhuang Y, Ye Z and Qian Q:
Current Progress in CAR-T cell therapy for hematological
malignancies. J Cancer. 12:326–334. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Siddiqi T, Soumerai JD, Dorritie KA,
Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong
L, Yang L, et al: Phase 1 TRANSCEND CLL 004 study of lisocabtagene
maraleucel in patients with relapsed/refractory CLL or SLL. Blood.
139:1794–1806. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Feng D and Sun J: Overview of anti-BCMA
CAR-T immunotherapy for multiple myeloma and relapsed/refractory
multiple myeloma. Scand J Immunol. 92:e129102020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Raje N, Berdeja J, Lin Y, Siegel D,
Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A,
et al: Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or
Refractory Multiple Myeloma. N Engl J Med. 380:1726–1737. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Curran E and O'Brien M: Role of
blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how
to sequence for patients with relapsed disease. Semin Hematol.
57:157–163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Fry TJ, Shah NN, Orentas RJ,
Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S,
Delbrook C, Yates B, et al: CD22-targeted CAR T cells induce
remission in B-ALL that is naive or resistant to CD19-targeted CAR
immunotherapy. Nat Med. 24:20–28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Xu J, Meng Q, Sun H, Zhang X, Yun J, Li B,
Wu S, Li X, Yang H, Zhu H, et al: HER2-specific chimeric antigen
receptor-T cells for targeted therapy of metastatic colorectal
cancer. Cell Death Dis. 12:11092021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Maggs L, Cattaneo G, Dal AE, Moghaddam AS
and Ferrone S: CAR T Cell-Based immunotherapy for the treatment of
glioblastoma. Front Neurosci. 15:6620642021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Rotte A, Frigault MJ, Ansari A, Gliner B,
Heery C and Shah B: Dose-response correlation for CAR-T cells: A
systematic review of clinical studies. J Immunother Cancer.
10:e0056782022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Dasyam N, George P and Weinkove R:
Chimeric antigen receptor T-cell therapies: Optimising the dose. Br
J Clin Pharmacol. 86:1678–1689. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Stefanski HE, Eaton A, Baggott C, Rossoff
J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA,
Moskop A, et al: Higher doses of tisagenlecleucel are associated
with improved outcomes: A report from the pediatric real-world CAR
consortium. Blood Adv. 7:541–548. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Frigault M, Rotte A, Ansari A, Gliner B,
Heery C and Shah B: Dose fractionation of CAR-T cells. A systematic
review of clinical outcomes. J Exp Clin Cancer Res. 42:112023.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Jogalekar MP, Rajendran RL, Khan F, Dmello
C, Gangadaran P and Ahn BC: CAR T-Cell-Based gene therapy for
cancers: New perspectives, challenges, and clinical developments.
Front Immunol. 13:9259852022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wagner DL, Koehl U, Chmielewski M, Scheid
C and Stripecke R: Review: Sustainable Clinical Development of
CAR-T Cells-switching from viral transduction towards CRISPR-Cas
Gene Editing. Front Immunol. 13:8654242022. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Gagelmann N, Riecken K, Wolschke C, Berger
C, Ayuk FA, Fehse B and Kröger N: Development of CAR-T cell
therapies for multiple myeloma. Leukemia. 34:2317–2332. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zeng W, Zhang Q, Zhu Y, Ou R, Peng L, Wang
B, Shen H, Liu Z, Lu L, Zhang P and Liu S: Engineering Novel
CD19/CD22 Dual-Target CAR-T cells for improved anti-tumor activity.
Cancer Invest. 40:282–292. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ghaffari S, Khalili N and Rezaei N:
CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer
immunotherapy. J Exp Clin Cancer Res. 40:2692021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Hong M and Chen YY: Killer fatigue:
Transition to NK-cell-like phenotype is a signature of CAR-T cell
exhaustion. Cell. 184:6017–6019. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Good CR, Aznar MA, Kuramitsu S, Samareh P,
Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y,
et al: An NK-like CAR T cell transition in CAR T cell dysfunction.
Cell. 184:6081–6100. e262021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Allen GM, Frankel NW, Reddy NR, Bhargava
HK, Yoshida MA, Stark SR, Purl M, Lee J, Yee JL, Yu W, et al:
Synthetic cytokine circuits that drive T cells into immune-excluded
tumors. Science. 378:eaba16242022. View Article : Google Scholar : PubMed/NCBI
|
